在纳塔利祖马布治疗期间管理多发性硬化症的再激活
Nathaniel Lizak1, Sifat Sharmin1, Dana Horáková2
1Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia.
概括
在natalizumab失败后切换到抗CD20疗法显著降低了多发性硬化症患者的复发风险. 继续使用纳塔利祖马布或转换为效率较低的治疗方法会增加复发风险,突出显示抗CD20药物是关键的替代品.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在多发性硬化症 (MS) 失败后切换疗法的有效性尚未确立.
- 在纳塔利祖马布失败后,考虑高效疗法,但直接比较是有限的.
研究的目的:
- 为了比较在MS患者中纳塔利祖马布失败后不同治疗策略的有效性.
- 为了评估复发风险,MRI活动,以及从纳塔利祖马布切换后残疾恶化.
主要方法:
- 对于在纳塔利祖马布治疗中复发的患者的MSBase注册表数据的回顾性分析.
- 纳塔利祖马布继续治疗的比较与切换到抗CD20药物,阿勒姆图祖马布,效率较低的疗法或停止治疗.
- 用于评估结果的多变量比例危险模型,并进行敏感性分析.
主要成果:
- 与纳塔利祖马布继续治疗相比,切换到抗CD20疗法与复发风险 (HR=0.48) 的显著降低有关.
- 降低治疗升级或停止治疗增加了复发风险 (HR=1.46和HR=2.08).
- 两组之间没有观察到MRI活动或残疾恶化的显著差异.
结论:
- 在纳塔利祖马布失败后切换到抗CD20疗法可能会显著降低MS复发风险.
- 虽然二次结果显示没有显著差异,但趋势表明潜在的好处.
- 临床医生可能会考虑抗CD20疗法作为natalizumab失败后的有效选择,等待对MRI和残疾结果的进一步研究.
相关概念视频
Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Myocarditis IV: Nursing Management
194
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
194
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
518
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
518
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Myocarditis III: Medical Management
160
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
160


